Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
A study to assess the safety and tolerability of AZD1152 in combination with low dose
cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three
patients to complete a 28 day cycle in the cohort, before the second three patients start
treatment.